Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 April 1994Website:
http://www.tenaxthera.comNext earnings report:
14 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:22:56 GMTDividend
Analysts recommendations
Institutional Ownership
TENX Latest News
Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference.
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast.
Tenax Therapeutics (NASDAQ: TENX ) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private placement has Tenax Therapeutics expecting $100 million in gross proceeds.
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $100 million to the Company, before deducting placement agent fees and other private placement expenses.
Tenax Therapeutics (NASDAQ: TENX ) stock is falling hard on Thursday after the pharmaceutical company announced details for a public offering of its shares. That public offering has Tenax Therapeutics selling 1.6 million units.
Shares of pharmaceutical specialist Tenax Therapeutics (NASDAD: TENX ) are skyrocketing on Monday amid encouraging regulatory news. More specifically, with a focus on addressing cardiovascular and pulmonary diseases with high unmet medical need, Tenax has received clearance for its investigational new drug (IND) application for its pulmonary hypertension therapeutic.
Shares of Tenax Therapeutics surged over 300% after it announced the US Food and Drug Administration has reviewed and cleared its Investigational New Drug (IND) application for its hypertension candidate, TNX-103. The specialty pharmaceutical company said the FDA's enables it to proceed with the first of two Phase 3 studies for TNX-103 (oral Levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
What type of business is Tenax Therapeutics?
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
What sector is Tenax Therapeutics in?
Tenax Therapeutics is in the Healthcare sector
What industry is Tenax Therapeutics in?
Tenax Therapeutics is in the Biotechnology industry
What country is Tenax Therapeutics from?
Tenax Therapeutics is headquartered in United States
When did Tenax Therapeutics go public?
Tenax Therapeutics initial public offering (IPO) was on 04 April 1994
What is Tenax Therapeutics website?
https://www.tenaxthera.com
Is Tenax Therapeutics in the S&P 500?
No, Tenax Therapeutics is not included in the S&P 500 index
Is Tenax Therapeutics in the NASDAQ 100?
No, Tenax Therapeutics is not included in the NASDAQ 100 index
Is Tenax Therapeutics in the Dow Jones?
No, Tenax Therapeutics is not included in the Dow Jones index
When was Tenax Therapeutics the previous earnings report?
No data
When does Tenax Therapeutics earnings report?
The next expected earnings date for Tenax Therapeutics is 14 May 2025